Endothelin receptor antagonists for pulmonary arterial hypertension-Reference-Cited by-同舟云学术

Endothelin receptor antagonists for pulmonary arterial hypertension

Published:2021-03-25 Issue:3 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Liu Chao¹,Chen Junmin²,Gao Yanqiu³,Deng Bao³,Liu Kunshen³

Affiliation:

1. Division of Cardiology; The First Hospital of Hebei Medical University; Shijiazhuang China

2. Department of Haematology and Rheumatology; The First Affiliated Hospital of Fujian Medical University; Fuzhou China

3. The First Hospital of Hebei Medical University; Shijiazhuang China

Publisher

Wiley

Subject

Pharmacology (medical)

Reference161 articles.

1. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension;Galie;New England Journal of Medicine,2015

2. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2;Galiè;Circulation,2008

3. US Food and Drug Administration Center for Drug Evaluation and Research Letairis (Ambrisentan) Tablets: Medical Review(s) www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022081Orig1s039.pdf

4. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2;Galiè;Circulation,2008

5. Bosentan therapy for pulmonary arterial hypertension;Rubin;New England Journal of Medicine,2002

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structural basis of antagonist selectivity in endothelin receptors;Cell Discovery;2024-07-30

2. Removing the FDA’s Boxed Hepatotoxicity Warning and Liver Function Testing Requirement for Ambrisentan;JAMA Network Open;2024-07-18

3. Emerging therapies targeting cardiovascular risk factors to prevent or delay the onset of heart failure;American Journal of Pharmacotherapy and Pharmaceutical Sciences;2024-07-09

4. Pulmonary Hypertension in Connective Tissue Diseases;Koşuyolu Heart Journal;2024-04-01

5. Novel insights and new therapeutic potentials for macrophages in pulmonary hypertension;Respiratory Research;2024-03-30